The first oral PCSK9 inhibitor, another study finding safe MRI scanning in patients with nonconditional CIEDs, the PFA-SHAM trial, and the curious case of orthopedic injuries in cardiology are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Enlicitide Approved
First Oral PCSK9 Inhibitor Welcomed for Potential Primary Care Impacthttps://www.medscape.com/viewarticle/first-oral-pcsk9-inhibitor-welcomed-potential-primary-care-2026a1000own
Dr Gregory Katz Substackhttps://gregorykatz.substack.com/p/are-we-sure-mercks-new-cholesterol
Expert Consensus Statement on Enhanced Radiation Protectionhttps://www.jacc.org/doi/10.1016/j.jcin.2026.06.011
'Shed the Lead' and the Injuries. Should Cath Labs Go Lead-Free?https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb
Health Hazards of Working in the Interventional Laboratoryhttps://doi.org/10.1016/j.jacc.2014.11.056
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD.https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Podden och tillhörande omslagsbild på den här sidan tillhör
Medscape. Innehållet i podden är skapat av Medscape och inte av,
eller tillsammans med, Poddtoppen.